B+
Bull case
25%
Probability
Target price
$38.00
+55.5% vs current
STRO
Sutro BiopharmaANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$27.00
+10.5% vs current
B-
Bear case
30%
Probability
Target price
$18.00
-26.3% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+59.7
Score
AI commentary
Primary-source support is real, but the evidence still points to a monitoring-style thesis: deterministic priors are negative, forward value realization depends heavily on one mid-2026 clinical event, and the peer set is loose. The recent financing and Astellas progress help, yet conviction should stay restrained until STRO-004 human data arrive.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-19catalystAACR 2026 pipeline visibilityMedium impact
AACR presentations scheduled for April 19-21, 2026 give near-term visibility into STRO-004, STRO-006, STRO-227 and the partnered TROP2 iADC, but this looks more like scientific framing than a decisive value inflection absent clearly differentiated data [#8-K-2026-03-23].
2026-06-30eventAstellas collaboration milestone receiptHigh impact
The partnered TROP2 dual-payload iADC has entered the clinic with patient dosing underway, and Sutro said the start triggered a $10 million milestone payment expected in Q2 2026; receipt would modestly reinforce external validation and liquidity, though not likely change the thesis alone [#8-K-2026-03-23].
2026-07-15eventSTRO-004 initial Phase 1 clinical dataHigh impact
Management said STRO-004 completed dosing across three cohorts and expects initial clinical data in mid-2026, including safety, PK exposure and potentially early activity; this is the clearest upside or downside driver because the program is the lead wholly owned clinical asset [#8-K-2026-03-23][#10-K-2026-03-23].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology